Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Opportunities to Optimize Cancer Policies Panel Discussion

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Advertisement

Advertisement




Sep
09
Today In Oncology
ELEVATE Trial Shows Disease-Free Survival Benefit With Adjuvant Ensartinib in ALK-Positive NSCLC
Prostate Cancer Higher Saturated Fat Intake May Be Linked to Worse Outcomes
Duane Mitchell Named Director of the UF Health Cancer Institute
Long-Course Chemoradiotherapy Shows Early Organ Preservation Advantage in Rectal Cancer
FDA Approves Camizestrant Combination Regimen for Locally Advanced or Metastatic Breast Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo